The Role of Presepsin and Procalcitonin in Early Diagnosis of Bacterial Infections in Cirrhotic Patients with Acute-on-Chronic Liver Failure.
Razvan Igna, Irina Gîrleanu, Camelia Cojocariu...
https://pubmed.ncbi.nlm.nih.gov/36143057Actively Recruiting
Age: 18Years +
All Genders
ID06224023
Predictive Values of Presepsin Levels in Ascites in Patients With Chronic Liver Failure
Led by Carol Davila University of Medicine and Pharmacy · Updated on 2024-08-21
30
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the predictive value of presepsin levels in ascites fluid among patients newly admitted with chronic liver failure. The study focuses on understanding whether presepsin, a fragment of the CD14 receptor involved in detecting bacterial components and triggering inflammation, can help predict outcomes in these patients. Previous studies suggested presepsin in blood may aid early infection diagnosis and mortality prediction in liver cirrhosis, but this study evaluates presepsin directly in ascites fluid. Participants will undergo a diagnostic procedure called paracentesis to collect ascites fluid, where presepsin levels will be measured. This observational study involves patients with chronic liver failure and ascites who meet technical requirements for safe paracentesis. No experimental treatments are given; instead, presepsin levels are monitored to assess their relationship with patient outcomes. During the study, participants will be followed for six months to observe mortality and the occurrence of infections, including spontaneous bacterial peritonitis and hepatic encephalopathy. Researchers will collect clinical data and monitor health status regularly to evaluate how presepsin levels in ascites correlate with these outcomes. The study aims to improve prognostic tools for people living with chronic liver failure and ascites.
CONDITIONS
Brief Title
Predictive Values of Presepsin Levels in ASciteS in Patients With Chronic Liver Failure
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Patient with ascites and chronic liver failure
- No contraindications and technical possibility to perform diagnostic paracentesis
- Age above 18 years old
- Informed consent
You will not qualify if you...
- Contraindications to paracentesis or technical impossibility to perform paracentesis
- Absence of informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - 1 day
Participants undergo a diagnostic paracentesis to determine presepsin levels in ascites.
1 visit (in-person)
Long-term Monitoring
Duration - 6 months
Participants are monitored for clinical outcomes including mortality, infections, and hepatic encephalopathy.
Follow-up visits as needed over 6 months
Trial Site Locations
Total: 1 location
1
"Agrippa Ionescu" Hospital
Bucharest, Romania
Actively Recruiting
Loading map...
Research Team
M
Mihai Ciocirlan
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Presepsin as a biomarker of inflammation and prognosis in decompensated liver disease.
Alberto Ferrarese, Mario Plebani, Anna Chiara Frigo...
https://pubmed.ncbi.nlm.nih.gov/33484772